EUVIMEDEUVIMED entdecken
Open Access

Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data

Salil V Deo iD, Giorgio Ciminata iD, Gauranga Mahalwar iD, Pedro R V O Salerno iD, David A McAllister iD, Yakov E Elgudin iD, Ariela Orkaby iD, Salim Virani iD, Stephen Fremes iD, Sanjay Rajagopalan iD, Naveed Sattar iD, Jill P Pell iD

Journal of the American Heart Association · 21.04.2026 · 15 (8)

DOI: 10.1161/jaha.124.040272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.04.2026. Verfasst von Salil V Deo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Louis Stokes Cleveland VA Medical Center Cleveland Ohio USA. Hauptthemen laut MEDLINE: Coronary Artery Bypass, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PCSK9 Inhibitors, Drug Costs. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lipid‐lowering therapy (LLT) is important for risk reduction for patients after coronary artery bypass grafting. Cost limits the wider use of PCSK9 (proprotein convertase subtilsin/kexin type 9) inhibitors (PCSK9is) and newer drugs. Hence, mathematical modeling was performed on a nationwide cohort of US veterans post coronary artery bypass grafting to understand the need for expensive drugs like PCSK9is and the cost effectiveness of this model was evaluated.

Methods

First, Monte Carlo simulations were used to model the stepwise initiation of high‐intensity statins, ezetimibe, and PCSK9i therapy for each patient to lower their low‐density lipoprotein cholesterol levels to recommended targets. Next, a lifetime Markov model was constructed with stroke, myocardial infarction, repeat revascularization, and mortality rates obtained our study cohort of nationwide US veterans post coronary artery bypass grafting. LLT treatment costs and quality adjusted life years were used to determine the cost effectiveness of this stepwise LLT approach versus observed clinical practice from the health care perspective. Probabilistic models were fit and results for cost effectiveness reported using incremental cost‐effectiveness ratio per quality adjusted life year gained over the lifetime.

Results

For 27 443 US veterans post‐ coronary artery bypass grafting (mean age 66 years, 10% Black) with a median low‐density lipoprotein cholesterol 129 (interquartile range, 95.2–180) mg/dL, the 42% and 37% reached target LLT by statin intensification only and including ezetimibe, respectively. Only 6% required bempedoic acid or PCSK9is after the preceding steps. Such stepwise LLT reduction projected 0.8 life years gained over the 30‐year period. With a median incremental cost‐effectiveness ratio of percent 15 232 (interquartile range, 13 520–17 769) per quality adjusted life year gained, this stepwise approach reached 100% probability for being cost effective (compared with observed clinical practice) at willingness‐to‐pay thresholds >$20 000.

Conclusions

Few patients needed bempedoic acid or PCSK9is when simulating stepwise LLT with high‐intensity statins and ezetimibe. Such an approach was observed as cost effective at very low willingness‐to‐pay thresholds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery BypassHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsDrug CostsCoronary Artery DiseaseAnticholesteremic AgentsDyslipidemiasHumansCost-Benefit AnalysisCost-Effectiveness AnalysisUnited StatesEzetimibeQuality-Adjusted Life YearsMarkov ChainsCholesterol, LDLMaleFemaleAgedTreatment OutcomeMonte Carlo MethodBiomarkersMiddle AgedProprotein Convertase 9Models, EconomicFatty Acids

Stichwörter der Autor:innen

Markov modelPCSK9 inhibitorbempedoic acidcost effectivenessezetimibelipid‐lowering therapystatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibePCSK9 InhibitorsCholesterol, LDLPCSK9 protein, humanBiomarkersProprotein Convertase 9Anticholesteremic AgentsFatty Acids

Autor:innen und Institutionen

  • Louis Stokes Cleveland VA Medical Center Cleveland Ohio USA.
  • Case Western School of Medicine Cleveland Ohio USA.
  • School of Health and Wellbeing University of Glasgow UK.
  • School of Health Technology and Assessment University of Glasgow UK.
  • Department of Medicine Cleveland Clinic Cleveland Ohio USA.
  • Harrington Heart and Vascular Institute Cleveland Ohio USA.

ORCID-Profile: Salil V Deo, Giorgio Ciminata, Gauranga Mahalwar, Pedro R V O Salerno, David A McAllister, Yakov E Elgudin, Ariela Orkaby, Salim Virani, Stephen Fremes, Sanjay Rajagopalan, Naveed Sattar, Jill P Pell

Zitieren

APA

Deo, S. V., Ciminata, G., Mahalwar, G., Salerno, P. R. V. O., McAllister, D. A., Elgudin, Y. E., Orkaby, A., Virani, S., Fremes, S., Rajagopalan, S., Sattar, N., & Pell, J. P. (2026). Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. Journal of the American Heart Association, 15(8). https://doi.org/10.1161/jaha.124.040272

Vancouver

Deo SV, Ciminata G, Mahalwar G, Salerno PRVO, McAllister DA, Elgudin YE, et al. Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. Journal of the American Heart Association. 2026;15(8). doi:10.1161/jaha.124.040272

BibTeX
@article{Deo2026,
  author = {Deo, Salil V and Ciminata, Giorgio and Mahalwar, Gauranga and Salerno, Pedro R V O and McAllister, David A and Elgudin, Yakov E and Orkaby, Ariela and Virani, Salim and Fremes, Stephen and Rajagopalan, Sanjay and Sattar, Naveed and Pell, Jill P},
  title = {Assessing the Cost Effectiveness of an Incremental Lipid‐Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1161/jaha.124.040272}
}
Kostenlos starten →